Clinical Trial Update: Bevacizumab, Erlotinib and Capecitabine for Advanced Pancreatic Cancer [Phase 1]

View source ↗

Summary

A Phase 1 trial of bevacizumab, erlotinib, and capecitabine in patients with advanced pancreatic cancer has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pancreatic Cancer

Drugs mentioned

• Bevacizumab (bevacizumab)
• Capecitabine (capecitabine)
• ERLOTINIB (Erlotinib)

Snippet

Sponsor: M.D. Anderson Cancer Center | Conditions: Pancreatic Cancer | Phase 1 | Status: COMPLETED